


# A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

Andrea Bertotti<sup>1,9</sup>, Giorgia Migliardi<sup>1,9</sup>, Francesco Galimi<sup>1</sup>, Francesco Sassi<sup>1,9</sup>, Davide Torti<sup>1,9</sup>, Claudio Isella<sup>2</sup>, Davide Corà<sup>3</sup>, Federica Di Nicolantonio<sup>4,12</sup>, Michela Buscarino<sup>4</sup>, Consalvo Petti<sup>2</sup>, Dario Ribero<sup>11</sup>, Nadia Russolillo<sup>11</sup>, Andrea Muratore<sup>5</sup>, Paolo Massucco<sup>5</sup>, Alberto Pisacane<sup>6</sup>, Luca Molinaro<sup>10</sup>, Emanuele Valtorta<sup>13</sup>, Andrea Sartore-Bianchi<sup>14</sup>, Mauro Risio<sup>6</sup>, Lorenzo Capussotti<sup>11</sup>, Marcello Gambacorta<sup>13</sup>, Salvatore Siena<sup>14</sup>, Enzo Medico<sup>2,9</sup>, Anna Sapino<sup>10</sup>, Silvia Marsoni<sup>7,15</sup>, Paolo M. Comoglio<sup>8,9</sup>, Alberto Bardelli<sup>4,9,12\*</sup>, and Livio Trusolino<sup>1,9,\*</sup>



## ABSTRACT

Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine. We produced large xenograft cohorts from 85 patient-derived, genetically characterized metastatic colorectal cancer samples ("xenopatients") to discover novel determinants of therapeutic response and new oncoprotein targets. Serially passaged tumors retained the morphologic and genomic features of their original counterparts. A validation trial confirmed the robustness of this approach: xenopatients responded to the anti-EGFR antibody cetuximab with rates and extents analogous to those observed in the clinic and could be prospectively stratified as responders or nonresponders on the basis of several predictive biomarkers. Genotype–response correlations indicated *HER2* amplification specifically in a subset of cetuximab-resistant, *KRAS/NRAS/BRAF/PIK3CA* wild-type cases. Importantly, *HER2* amplification was also enriched in clinically nonresponsive *KRAS* wild-type patients. A proof-of-concept, multiarm study in *HER2*-amplified xenopatients revealed that the combined inhibition of *HER2* and EGFR induced overt, long-lasting tumor regression. Our results suggest promising therapeutic opportunities in cetuximab-resistant patients with metastatic colorectal cancer, whose medical treatment in the chemorefractory setting remains an unmet clinical need.

**SIGNIFICANCE:** Direct transfer xenografts of tumor surgical specimens conserve the interindividual diversity and the genetic heterogeneity typical of the tumors of origin, combining the flexibility of preclinical analysis with the informative value of population-based studies. Our suite of patient-derived xenografts from metastatic colorectal carcinomas reliably mimicked disease response in humans, prospectively recapitulated biomarker-based case stratification, and identified *HER2* as a predictor of resistance to anti-epidermal growth factor receptor antibodies and of response to combination therapies against *HER2* and epidermal growth factor receptor in this tumor setting. *Cancer Discovery*; 1(6); 508–23. ©2011 AACR.

## INTRODUCTION

With a global incidence of more than one million cases and a disease-specific mortality of approximately 33% in the developed world, colorectal cancer is a major health burden (1). Despite the introduction of both newer cytotoxic chemotherapies and novel biologic agents, overall progress has been more modest than had been hoped, and metastatic colorectal cancer remains, for the most part, incurable (2).

**Authors' Affiliations:** <sup>1</sup>Laboratory of Molecular Pharmacology, <sup>2</sup>Laboratory of Oncogenetics, <sup>3</sup>Laboratory of Systems Biology, <sup>4</sup>Laboratory of Molecular Genetics, <sup>5</sup>Division of Surgical Oncology, <sup>6</sup>Unit of Pathology, <sup>7</sup>Clinical Coordination Unit, and <sup>8</sup>Molecular Clinical Oncology, Institute for Cancer Research and Treatment, Torino; Departments of <sup>9</sup>Oncological Sciences and <sup>10</sup>Biomedical Sciences and Human Oncology, University of Torino Medical School, Torino; <sup>11</sup>Department of Surgery, Mauriziano Umberto I Hospital, Torino; <sup>12</sup>FIRC Institute of Molecular Oncology, Milano; <sup>13</sup>Division of Pathology, <sup>14</sup>Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milano; and <sup>15</sup>Southern Europe New Drug Organization Foundation, Milano, Italy

**Note:** Supplementary data for this article are available at *Cancer Discovery* Online (<http://www.cancerdiscovery.aacrjournals.org>).

\*These authors contributed equally to this work as senior authors.

**Corresponding Authors:** Livio Trusolino and Andrea Bertotti, Laboratory of Molecular Pharmacology, Institute for Cancer Research and Treatment, Strada Provinciale 142, km 3.95, 10060 Candiolo, Torino, Italy. Phone: 39-011-993.32.02; Fax: 39-011-993.32.25; E-mail: livio.trusolino@ircc.it; and Andrea Bertotti, andrea.bertotti@ircc.it

doi: 10.1158/2159-8290.CD-11-0109

©2011 American Association for Cancer Research.

As for other types of malignancy, colorectal cancer is not a homogeneous disease but actually comprises multiple entities that vary in natural history and molecular pathogenesis. This heterogeneity explains why molecular cancer therapeutics against individual disease driver targets have proven to be effective in only a fraction of cases. One prototypical example is provided by the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab, which are approved for the treatment of metastatic colorectal cancer. In unselected patients, the extent of clinical benefit from monotherapy with either drug hovers near the threshold for statistical significance, with response rates of approximately 10% (3–5).

The population of potential responders has been recently enriched thanks to a biomarker-development strategy that is driven by the plausible biological rationale that constitutive activation of signaling pathways parallel to or downstream from EGFR, such as the RAS-RAF axis, should circumvent EGFR inhibition and therefore preclude sensitivity to EGFR-targeted agents (6). Indeed, the authors of both retrospective and prospective trials have convincingly demonstrated the inefficacy of EGFR-neutralizing antibodies in metastatic colorectal cancer patients with common (codons 12 and 13) *KRAS* mutations (7–12).

Along this line, in a number of retrospective studies investigators have provided initial evidence that rare *KRAS* mutations as well as *NRAS*, *BRAF*, and (possibly) *PIK3CA* mutations also are significantly associated with low response rates (13–16). When considering the cumulative incidence of

these genetic alterations in all metastatic colorectal cancers, more than 50% of tumors are expected to be resistant to EGFR-targeted antibodies (16). Yet, the overall picture is far from complete: among the subpopulation that carries wild-type *KRAS* alleles, objective response to single-agent anti-EGFR treatment is still confined to 13% to 17% of cases (4, 5, 17, 18).

Although prospective exclusion from treatment of *NRAS*, *BRAF*, *PIK3CA*, and rare *KRAS* mutations will likely lead to a further increase in the percentage of responders, the paucity of therapeutic opportunities remains evident. Patient stratification needs to be refined with further validation of existing biomarkers and with the identification of novel ones; perhaps more importantly, best supportive care remains the only therapeutic option for the large fraction of subjects with cetuximab- or panitumumab-resistant tumors once they become refractory to standard chemotherapy. We decided to address at least some of these unmet medical needs through a preclinical effort that embodied prospective, randomized trials in mice.

To this aim, we took advantage of patient-derived direct transfer xenografts of a large series of liver metastases from colorectal cancers, part of which had been previously deployed for unrelated work (19). We structured the study in 2 consecutive and complementary parts. The first setting was a reverse-validation analysis in which existing clinical information was exploited to understand how closely our approach recapitulated the situation in patients with colorectal cancer. The second setting was an exploratory, proof-of-concept study in which we sought to identify new molecular biomarkers of resistance to anti-EGFR antibodies and test their potential as alternative therapeutic targets. Results from these investigations support the use of direct transfer xenografts as a reliable strategy to anticipate clinical findings, provide direction for optimizing personalized treatment in metastatic colorectal cancers, and suggest novel treatment opportunities in patients with no other therapeutic options.

## RESULTS

### Setup and Characterization of the Xenopatient Platform

We undertook a systematic effort aimed to build a biobank of surgical material stored under viable conditions and serially propagated in mouse recipients, starting from colorectal cancer liver metastases (19). A summary of the clinical and molecular characteristics for the study population can be found in Table 1 and detailed information is provided in Supplementary Tables S1 and S2. For each tumor specimen, some fragments were processed *ad hoc* for pathologic and molecular characterization; 2 others were subcutaneously implanted in 2 different mice and then expanded to generate a pair of independent xenograft lines ("xenopatients") from the same patient tumor (Fig. 1A).


By combining the use of severely immunocompromised nonobese diabetes/severe combined immunodeficiency animals with optimization of patient-to-mouse transfer procedures, we were able to achieve a large percentage of successful engraftments, with 130 of 150 consecutive specimens (87%) giving rise to transplantable tumors. Therefore,

**Table 1. Summary of the clinical and molecular characteristics for the study cohort**

|  |
|--|
| Sex (n = 150), n (%)                   |
| Male, 100 (67)                         |
| Female, 50 (33)                        |
| Age (n = 145), y                       |
| Median, 64                             |
| Range, 45–87                           |
| Site of primary (n = 129), n (%)       |
| Colon, 100 (78)                        |
| Rectum, 29 (22)                        |
| Diagnosis (n = 128), n (%)             |
| Synchronous, 69 (54)                   |
| Metachronous, 59 (46)                  |
| Previous chemotherapy (n = 128), n (%) |
| Yes, 46 (36)                           |
| No, 81 (64)                            |
| Neoadjuvant (n = 128), n (%)           |
| Yes, 76 (61)                           |
| No, 48 (39)                            |
| <i>KRAS</i> status (n = 139), n (%)    |
| Codon 12, 40 (29)                      |
| Codon 61, 1 (0.7)                      |
| Codon 13, 10 (7.2)                     |
| Codon 146, 4 (2.9)                     |
| <i>BRAF</i> status (n = 138), n (%)    |
| Codon 600, 3 (2.2)                     |
| <i>NRAS</i> status (n = 138), n (%)    |
| Codon 12, 2 (1.4)                      |
| Codon 61, 6 (4.3)                      |
| <i>PIK3CA</i> status (n = 138), n (%)  |
| Codon 545, 5 (3.6)                     |
| Codon 546, 1 (0.7)                     |
| Codon 1047, 7 (5)                      |

we can reasonably exclude any strong bias towards selection of more aggressive cases in our set of xenografts. It is worth noting that the 20 tumors that failed to engraft tended not to harbor mutations in *KRAS*, *NRAS*, *BRAF*, and *PIK3CA*; specifically, of the 14 samples for which genetic information was available, only 2 proved to be mutated (one for *KRAS* and another for *PIK3CA*; Supplementary Table S2). Although this finding might indicate a potential association between engraftment efficiency and mutational status, the numerosness and high take rate of implanted tumors allowed a representation of wild-type and mutated cases at frequencies similar to those described in other series of metastatic colorectal cancers (16).





**Figure 1.** Setup and characterization of the xenopatient platform. **A**, generation of xenopatients. After surgical removal from patient, each metastatic colorectal cancer specimen was cut in small pieces and 2 fragments were implanted in 2 mice. After engraftment and tumor mass formation, the tumors were passaged and expanded for 2 generations until production of 2 cohorts, each consisting of 12 mice. These were randomized for treatment with placebo (6 mice) or cetuximab (6 mice). **B**, xenografted tumors retained the histopathologic characteristics of original samples. Hematoxylin and eosin stains of representative cases with different morphologic features. In some instances, both fresh and passaged lesions displayed a well-differentiated phenotype, with cells describing irregular pluristratified tubular/acinar structures with multiple lumens embedded in a scarce stromal matrix. Other samples had a clear-cell appearance or featured high nuclear grade and areas of necrosis. In some cases, discohesive mucus-secreting cells defined a moderately differentiated phenotype typical of mucinous adenocarcinoma, with signet-ring elements showing peripheral nuclear delocalization and abundant intervening stroma associated with desmoplastic reaction. Finally, a few tumors exhibited high-grade pleomorphism and could be pathologically classified as poorly differentiated adenocarcinomas. Scale bar, 50  $\mu$ m. **C**, genetic concordance between xenografts and their original counterparts. Similar groups of samples are evidenced by applying a Pearson-based hierarchical clustering to copy number calls (see the Methods for details).

To rule out any major phenotypic drift that xenografted specimens might have acquired as the result of sequential passaging, we compared the histological aspects of the tumors grown in mice (explanted after the second *in vivo* passage) with those of the corresponding original metastasis in 22 randomly selected cases. In line with previous findings (20), we observed substantial preservation of morphologic traits between patient-derived and mouse-derived tumors (Fig. 1B).

Mouse-passaged colorectal cancer samples have already been used for genome-wide mutational studies and for copy number variation surveys (21, 22). Although genetic coherence between fresh and mouse-expanded material has been demonstrated in the case of missense mutations (23), a systematic comparative assessment of gene copy number changes has not been attempted. We therefore used single-nucleotide polymorphism arrays to obtain an unbiased copy number assessment of 39 tumors derived from 4 different patients. For each patient, we analyzed the DNA derived from different sources: (i) normal liver; (ii) original liver metastasis; (iii) mouse-grown tumors explanted after the first passage *in vivo* (1 or 2 samples per patient); and (iv) mouse-grown tumors explanted after the second passage *in vivo* (4 or 8 samples per patient).

We detected largely concordant copy number variations between first- and second-passage xenografts and their matched original counterparts, whereas a marked heterogeneity was observed among tumors belonging to different individuals (Fig. 1C and Supplementary Fig. S1). For some loci, genomic consistency was greater among propagated samples than between passaged and fresh specimens (Supplementary Fig. S1). This finding is likely attributable to substitution of human stroma with host murine components during serial expansion *in vivo*; because the single-nucleotide polymorphism probes are human-specific, dilution of tumor genomic content by DNA from the normal human microenvironment occurs in original samples but not in xenografted tumors. The same set of fresh and passaged specimens also was profiled for *KRAS*, *NRAS*, *BRAF*, and *PIK3CA* mutations in multiple hotspots. Genetic lesions detected in the original samples were maintained in the xenografted tumors (which did not display further mutations in the examined genes), and wild-type cases persisted unaltered throughout serial passaging (Supplementary Table S2). Overall, these results reinforce the notion that tumors largely retain their phenotypic and genomic characteristics during early passages in mice and substantiate the potential of patient-derived xenografts as faithful aliases of human patients for preclinical studies.

### Design of Reverse Validation Trial with Cetuximab

The trial was performed on 85 metastatic colorectal cancer samples that had successfully engrafted. Of these, 2 (2.3%) displayed high-grade microsatellite instability (Supplementary Table S2), consistent with the 1.3% to 2.7% frequency already described in metastatic colorectal cancer (13, 24). Xenografts were propagated through double-step *in vivo* passaging, and treatment cohorts of 12 mice were generated from each implanted specimen. In 57 cases (67%) we obtained productive development of 2 independent cohorts from 2 different fragments of the same original tumor; for the remaining 28 samples (33%) engraftment occurred in just one animal, and only one cohort was obtained. When tumors in each cohort

reached an average volume of 400 mm<sup>3</sup>, mice were randomized to receive either placebo or cetuximab (Fig. 1A). On the basis of this experimental pipeline, we denominate “case” as the average performance of 1 or (more frequently) 2 lines of xenopatient from one single patient.


For assessment of tumor response to therapy, we used volume measurements and adopted a classification methodology loosely inspired by clinical criteria: (i) tumor regression (or shrinkage) was defined as a decrease of at least 50% in the volume of target lesions, taking as reference the baseline tumor volume; (ii) at least a 35% increase in tumor volume identified disease progression; and (iii) responses that were neither sufficient reduction to qualify for shrinkage nor sufficient increase to qualify for progression were considered as disease stabilization.

We designed the experiments following a historical perspective. In a first phase, the trial was performed on an initial unselected population of 47 cases. All cohorts were treated with cetuximab or placebo independent of *KRAS* mutational status to analyze whether *KRAS*-mutant xenopatient were in fact resistant to anti-EGFR treatment and to compare our response rates with those from the first trials in the pre-*KRAS* selection era. In the second phase, *KRAS*-mutant tumors were spared from treatment, and cetuximab was given to 38 newly accrued cases who exhibited wild-type *KRAS* (and included, however, all other mutant genotypes). Hence, this second part of the trial recapitulated the current guidelines for EGFR-targeted therapy in metastatic colorectal cancers.


### Effect of Cetuximab Treatment in Patient-Derived Metastatic Colorectal Cancer Xenografts and Biomarker Analysis

A first evaluation was scheduled 3 weeks after treatment initiation. In an unselected population of 47 metastatic colorectal cancers, we observed tumor shrinkage in 5 cases (10.6%), disease stabilization in 14 cases (29.8%), and progression in 28 cases (59.6%; Fig. 2A and B and Supplementary Table S2). Tumors displaying regression or stabilization continued treatment for additional 3 weeks. At this second time point, shrinkage was confirmed in 5 cases and was monitored in 2 other cases that had experienced previous stabilization; stable disease was maintained in 8 cases and turned into progression in 4 cases (Supplementary Fig. S2). Collectively, these response rates are consistent with those obtained in unselected patients treated with single-agent cetuximab or panitumumab. By performing a meta-analysis of the available data on the activity of anti-EGFR monotherapy in both heavily pretreated and chemo-naïve subjects, regardless of *KRAS* status, we found that average objective response was 10% (range 8%–11.6%) and stable disease occurred in 30% of cases (range 24%–37%) (4, 5, 25–29).

When reconsidering response rates according to the mutational status of *KRAS*, we found that neither regression nor disease stabilization was achieved in any of the 18 cohorts bearing *KRAS*-mutant (codons 12 and 13) tumors (38.3%; Fig. 2A, Supplementary Fig. S2, and Supplementary Table S2), which again is in agreement with clinical evidence (7–12). Two *KRAS*-mutant cases displayed stable disease at the first 3-week evaluation time point, but they underwent progression in the following 3 weeks (Supplementary Fig. S2).



**Figure 2.** Effect of cetuximab treatment in unselected metastatic colorectal cancer xenopatiens. **A**, waterfall plot of cetuximab response after 3 weeks of treatment, compared with tumor volume at baseline, in an unselected population of 47 cases. Dotted lines indicate the cut-off values for arbitrarily defined categories of therapy response: cases experiencing disease progression, stabilization, or regression are shaded in light brown, light yellow, and light aquamarine, respectively. Asterisks denote the samples for which growth curves are shown in panel B. **B**, representative tumor growth curves in cohorts derived from individual patients, treated with placebo (gray) or cetuximab (red). *n* = 6 for each treatment arm. R, regression/shrinkage; S, stabilization/disease control; S/P, initial stabilization followed by tumor progression; P, progression/lack of response.



Having confirmed that KRAS-mutant metastatic colorectal cancers were resistant to cetuximab in this first series of consecutive samples, we elected to exclude from treatment all additional cases with codon 12 and 13 mutations. Figure 3A displays the effect of cetuximab administration in the overall KRAS (codons 12 and 13) wild-type population after 3 weeks;


the plot comprises a total of 66 wild-type tumors, 28 from the first series and 38 collected thereafter. In this patient subgroup, tumor regression increased to 16.7% (11 cases), disease stabilization rate was 40.9% (27 cases), and tumor progression rate was 42.4% (28 cases; Fig. 3A and Supplementary Table S2). At the 6-week time point, disease stabilization

Downloaded from <http://aacrjournals.org/cancerdiscovery/article-pdf/16/508/1848077/508.pdf> by guest on 22 October 2024

changed to tumor shrinkage in 3 cases and developed into disease progression in 7 cases (Supplementary Fig. S3 and Table S2). Once more, these distributions are in agreement with clinical studies in chemotherapy-refractory metastatic colorectal cancer patients in which the authors describe a

response rate of 12.8% to 17% and disease stabilization in 34% of *KRAS* (codons 12 and 13) wild-type patients (17, 18).

In a number of retrospective studies investigators have suggested that mutations in other downstream effectors of the EGFR signaling pathway, such as *NRAS*, *BRAF*, and *PIK3CA*,



**Figure 3.** Effect of cetuximab treatment in *KRAS* wild-type metastatic colorectal cancer xenopatients and biomarker correlations. **A**, waterfall plot of cetuximab response after 3 weeks of treatment, compared with tumor volume at baseline, in a *KRAS* wild-type population of 66 cases. **B**, distribution of response rates on the basis of *EGFR* copy number (CN) in *KRAS* wild-type xenopatients and in the quadruple-negative subpopulation. *EGFR* copy number was arbitrarily defined as a gain when more than three *EGFR* gene copies were detected by quantitative PCR analysis on genomic DNA. Differences in distribution were statistically significant both in *KRAS* wild-type xenopatients ( $P < 0.001$  by  $\chi^2$  test) and in the quadruple-negative subpopulation ( $P < 0.05$  by  $\chi^2$  test). **C**, expression analysis of amphiregulin (AREG) and epiregulin (EREG) in 54 *KRAS* wild-type tumors. When combining tumors that responded to cetuximab with disease regression or stabilization, the median expression of AREG was significantly greater than in the group of tumors that progressed. EREG was also more expressed in tumors that responded to cetuximab with shrinkage or stabilization than in resistant cancers, but this difference did not reach statistical significance.  $**P < 0.01$  by 2-tailed Student *t* test. R, regression; S, stabilization; P, progression.

Downloaded from <http://aacrjournals.org/cancerdiscovery/article-pdf/1/6/508/1848077/508.pdf> by guest on 22 October 2024



might also have a negative effect on response to anti-EGFR antibodies (13–16). Because our *KRAS* (codons 12 and 13) wild-type subpopulation included all these genotypes and additional *KRAS* rare mutations at codons 61 and 146, we decided to exploit our platform to challenge the predictive value of these emerging biomarkers. Our results prospectively validated observations in patients: none of the 7 *NRAS*- and 3 *BRAF*-mutant cases (10.6% and 4.5%, respectively) or the 4 cases with *KRAS* rare mutations (6.1%) responded to cetuximab with tumor shrinkage or stabilization.

Four tumors (6.1%) harbored a *PIK3CA* mutation without concurrent *KRAS* mutations; of these, 3 (1 exon 9 and 2 exon 20 mutants) progressed, and 1 (exon 20) regressed (Fig. 3A and Supplementary Fig S3, and Table S2). These results are partially at odds with previous reports in which authors suggest that mutations in exon 20, but not exon 9, predict worse outcome after the administration of cetuximab (14–16). However, because of the low number of patients both in our series and in the previous studies, the impact of this potential “exon-specific” effect remains uncertain. When we restricted the analysis to the “quadruple-negative” subset exhibiting wild-type *KRAS*, *NRAS*, *BRAF*, and *PIK3CA*, the percentage of responders was enriched up to 20.8% and disease stabilization increased to 56.3%.

We further assessed the predictive power of additional biomarkers that have been proposed as positive determinants of sensitivity to cetuximab. An increase in *EGFR* gene copy number, usually because of a variable degree of chromosome 7 polysomy rather than locus-specific amplification, has been found to correlate with response to anti-EGFR therapies (30–33). In *KRAS* wild-type tumors, it has been demonstrated that patients with an *EGFR* FISH-positive phenotype show greater response rates (71%) compared with patients with normal *EGFR* copy number (37%) (34). In our series, *EGFR* copy number gain (as assessed by quantitative PCR) was detected in 23 of 66 *KRAS* (codons 12 and 13) wild-type cases (34.8%) and was associated with regression in 7 cases (30.4%), stabilization in 12 cases (52.2%), and progression in 4 cases (17.4%). The 43 tumors with normal *EGFR* copy number (65.2%) displayed shrinkage in 4 cases (9.3%), stabilization in 15 cases (34.9%), and progression in 24 cases (55.8%; Fig. 3B and Supplementary Table S2). The frequency of disease stabilization in tumors with *EGFR* copy number gain was even greater when considering only the “quadruple-negative” subpopulation (Fig. 3B). Therefore, *EGFR* copy number gain tended to segregate responders also in our pre-clinical context.

Preliminary evidence from small series and larger retrospective studies have shown an association between expression of amphiregulin and epiregulin, 2 EGFR ligands, and clinical outcome (35, 36). In patients with wild-type *KRAS* tumors, a significant association was observed between ligand expression and tumor shrinkage or stabilization; however, objective responses were also detected in patients with low ligand expression (36). Again, our preclinical trial provided analogous information. When we performed quantitative reverse transcription-PCR on the original material of 54 *KRAS* wild-type tumors, we noticed a trend toward greater median expression of both amphiregulin and epiregulin in responders, but cases of tumor regression also occurred in tumors with low ligand expression (Fig. 3C and Supplementary Table S2).

## Correlation of *HER2* Amplification with Therapeutic Resistance to Cetuximab


Despite the enrichment in responders and the greater frequency of stable disease compared with the *KRAS* wild-type (codons 12 and 13) subpopulation, 11 of 48 cases (22.9%) with quadruple-negative tumors proved to be resistant to cetuximab (Fig. 3A). Similar resistance rates for the same genetically defined subgroup have been described in retrospective clinical studies (16). This finding calls for the identification of other molecular determinants responsible for *de novo* therapeutic resistance within this patient subset. This task is further supported by the notion that resistance biomarkers, if druggable, can represent alternative therapeutic targets *per se*.

Overexpression of receptor tyrosine kinases (RTK) other than EGFR has been shown to obviate the need for activated EGFR signaling and be responsible for resistance to anti-EGFR therapies in various tumor settings (37). We therefore concentrated on RTKs known to be deregulated in colorectal cancer. Genome-wide expression profiling in a suite of 137 metastatic colorectal cancers that included most of the *KRAS* wild-type tumors used in our reverse validation trial with cetuximab (51 of 66, 77%) indicated high-level expression of a number of RTKs in individual samples. Among these, *HER2* stood out from the survey because of the presence of 3 outliers featuring massive receptor overexpression (2.2%; Fig. 4A). This prevalence is in agreement with other population studies, which report *HER2* overexpression in 2% to 3.5% of genetically unselected colorectal cancers as a consequence of locus-specific gene amplification (38–40). We confirmed this prevalence in a second independent case series: tissue microarray-based analysis of 112 metastatic colorectal cancer archival specimens revealed concordant HercepTest and FISH positivity for *HER2* overexpression/amplification in 3 cases (2.7%; Fig. 4B).

When performing genotype-response correlations, we found that the 3 *HER2*-overexpressing outliers pinpointed by genome-wide transcriptional analysis (M051, M077, and M091) all fell within the quadruple-negative subset and all displayed unquestionable resistance to cetuximab (Supplementary Fig. S4). The collection used for gene expression profiling contained only 7 of the 11 cetuximab-resistant cases with a quadruple-negative genotype present in our set of *KRAS* wild-type xenopatient. To extend our survey and to support expression data with genetic information, we performed quantitative PCR gene copy number analysis on the whole panel of cetuximab-resistant, quadruple-negative cases. Genomic amplification of *HER2* was confirmed in the 3 expression outliers previously identified by gene expression analysis and was found in a fourth case (M147; Fig. 4C and Supplementary Fig. S4); results were validated by FISH (Fig. 4C). Therefore, the prevalence of *HER2* amplification increased from 2% to 3% to more than 36% (4/11) when we considered cases resistant to cetuximab that were wild-type for *KRAS*, *NRAS*, *BRAF*, and *PIK3CA* (Fig. 4D).


To establish the clinical relevance of these results, we explored whether *HER2* was overexpressed and/or amplified in tumors from patients that exhibited resistance to anti-EGFR antibodies. We started with a retrospective analysis of





**Figure 4.** Correlation between *HER2* amplification and therapeutic resistance to cetuximab in xenopatients. **A**, distribution of *HER2* expression levels in a series of 137 metastatic colorectal cancer samples, as assessed by oligonucleotide microarrays. *HER2* expression in the outliers was more than 2 SDs from the mean. **B**, *HER2* expression (HercepTest, top) and *HER2* gene copy number (FISH, bottom) in representative cases extracted from tissue microarray analysis of an independent series of 112 metastatic colorectal cancer archival specimens. **C**, evidence of *HER2* amplification in our series of cetuximab-resistant, quadruple-negative tumors. Left: quantitative PCR gene copy number analysis. Dotted line indicates 2 copies. Right: FISH analysis of *HER2* amplification in a cetuximab-resistant, quadruple-negative case (M077). Shown are samples from the original liver metastasis and from the mouse xenograft. The *HER2* gene is indicated by red dots, whereas the control chromosome 17 centromeric probe (CEP17) is labeled in green. **D**, genotype-response correlations in the *KRAS* wild-type subpopulation as previously shown in Figure 3A. Light gray histograms indicate cases with rare mutations of *KRAS* or mutations of *NRAS*, *BRAF*, and *PIK3CA*.

Downloaded from <http://aacrjournals.org/cancerdiscovery/article-pdf/16/508/1848077/508.pdf> by guest on 22 October 2024



**Figure 5.** Correlation between *HER2* amplification and therapeutic resistance to cetuximab in human patients. **A**, *HER2* expression (HercepTest, top) and *HER2* gene copy number (FISH, bottom) in representative cases of cetuximab-resistant, *KRAS* wild-type tumors in human patients. Patients evaluated in this cohort were selected on the basis of evidence that treatment outcome could be attributable only to administration of either cetuximab or panitumumab. For those patients who progressed on irinotecan-based chemotherapy, cetuximab was administered in combination with irinotecan given at the same dose and schedule previously used. Clinical response was assessed with radiologic examination (computed tomography or magnetic resonance imaging). The Response Evaluation Criteria in Solid Tumors (RECIST 1.1) were adopted for evaluation. **B**, prevalence of *HER2* amplification in unselected metastatic colorectal cancer patients, according to published information as well as data from our tissue microarray analysis (38–40) (left), and in cetuximab-resistant, genetically selected patients (middle) and xenopatients (right). *P* values were calculated by the 2-tailed binomial distribution test.

cases collected at our institutions. In 17 *KRAS* wild-type metastatic colorectal cancers from patients who had not received a clinical benefit from either cetuximab or panitumumab (16 progressive diseases and 1 ephemeral stabilization that shortly turned into progressive disease), we found 3 cases with a positive (3+) HercepTest and diffuse, high-grade amplification of *HER2* (3/17, 17.6%; Fig. 5A and Supplementary Table S3). In contrast, no HercepTest-3+ overexpression or homogeneous amplification of *HER2* could be detected in any of 14 *KRAS* wild-type tumors from patients in which anti-EGFR treatment had induced disease control (9 objective responses and 5 long-lasting stable diseases; Supplementary Table S3).

Then, we searched for *HER2*-overexpressing outliers by using publicly available gene expression datasets annotated for response to anti-EGFR antibodies. The first database comprises 59 colorectal carcinomas, including 39 *KRAS* wild-type cases; among this latter group, 20 tumors are reported to be cetuximab-sensitive (objective response or stable disease), and 19 are defined as cetuximab-resistant (progressive disease) (35); a second independent database encompasses 19 *KRAS* wild-type tumors, of which 11 are annotated as cetuximab-sensitive and 8 as cetuximab-resistant (41). Results from this analysis were consistent with data from our internal series. In the first collection, 2 *HER2* overexpressors could be identified (Supplementary Fig. S5): both were wild-type for *KRAS*

and segregated in the subset of cetuximab-resistant tumors (2/19, 10.5%) (35). The second dataset reported the presence of 1 case featuring *HER2* overexpression, which was categorized as a nonresponder (1/8, 12.5%) (41). Collectively, these figures indicate a frequency of *HER2* amplification/overexpression in 13.6% of patients with *KRAS* wild-type tumors that progressed on cetuximab or panitumumab (6/44; Fig. 5B), with no evidence of *HER2* amplification in any of the 45 patients in which anti-EGFR therapy was effective ( $P < 0.05$  by the Fisher exact test). Although limited in number, these findings strongly suggest that *HER2* amplification is a negative determinant of response to anti-EGFR antibodies in metastatic colorectal cancers that do not harbor genetic alterations of the RAS pathway.

### Therapeutic Opportunities for Cetuximab-Resistant, *HER2*-Amplified Colorectal Tumors

We reasoned that *HER2* amplification could represent not only a biomarker of resistance to EGFR inhibition but also a positive predictor of response to *HER2*-targeting agents. Furthermore, *HER2* inhibition could restore sensitivity to anti-EGFR therapies. To assess the validity of *HER2* as a therapeutic target in cetuximab-resistant metastatic colorectal cancers, we exploited the experimental merits of our xenopatient platform by executing a proof-of-principle, multiarm “xenotrial” in 2 representative cases (M077 and M091). As for

the choice of therapeutic regimens, we focused on dual inhibitors of HER2 and EGFR that were administered individually, together, or in combination with cetuximab. We selected pertuzumab, a recombinant humanized monoclonal antibody that disrupts HER2 heterodimerization with EGFR and with other HER partners (42), and lapatinib, a small molecule inhibitor with high selectivity for both HER2 and EGFR (43). For each case, the original tumor specimen was serially passaged *in vivo* until production of 30 tumor-bearing animals. When xenografts reached an average volume of approximately 400 mm<sup>3</sup>, mice were randomized into 6 independent treatment cohorts, each consisting of 5 xenopatient: (i) vehicle (placebo); (ii) pertuzumab alone; (iii) pertuzumab and cetuximab; (iv) lapatinib alone; (v) lapatinib and cetuximab; and (vi) lapatinib and pertuzumab.

At the first evaluation time point after 3 weeks of treatment, case M077 proved to be completely insensitive to pertuzumab alone (tumor volume variation compared with volume at baseline: +196%). The combination of pertuzumab and cetuximab produced only a negligible growth delay (+123%), after which mice needed to be killed. Lapatinib alone displayed stronger activity and induced disease stabilization (+10%). Intriguingly, the association of lapatinib and pertuzumab or lapatinib and cetuximab resulted in significant tumor volume reduction, with the former combination being more effective (−75% for pertuzumab + lapatinib and −41% for cetuximab + lapatinib; Fig. 6A). Tumor regression in all arms treated with antibody and lapatinib became massive in the second 3-week observation period (−93% for pertuzumab + lapatinib and −79% for cetuximab + lapatinib), whereas disease stabilization produced by lapatinib alone tended to attenuate over time (+37%; Fig. 6A).

Of note, delayed addition of lapatinib in a treatment arm that had received only pertuzumab for the first 4 weeks rendered pertuzumab-insensitive, exponentially growing tumors fully responsive to the combination therapy, with rapid and dramatic tumor shrinkage (Supplementary Fig. S6A). Response of case M091 to the same treatment modalities was similar, with some minor differences. In line with the results obtained in M077, pertuzumab alone was completely ineffective (+237% after 3 weeks of therapy), whereas the combination of pertuzumab and lapatinib led to overt tumor regression (−65% after 3 weeks and −64% after 6 weeks). Again, in accordance with the findings in case M077, the effect of cetuximab + lapatinib was considerable but less pronounced than that exerted by pertuzumab + lapatinib (−53% after 3 weeks and −45% after 6 weeks). Unlike case M077, disease stabilization was induced by double therapy with pertuzumab and cetuximab (−11% after 3 weeks and +15% after 6 weeks) but not by lapatinib alone (+163% after 3 weeks; Fig. 6B).

*In situ* examination of representative tumors from case M077 by the use of phospho-specific antibodies directed against HER2 and EGFR downstream transducers revealed that treatments were efficacious only when they fully neutralized signal activity. Phosphorylation of the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase substrate and of the phosphoinositide 3-kinase distal effector S6 was impaired very weakly by pertuzumab alone or by pertuzumab + cetuximab (Supplementary Fig. S6B) and only


partially by lapatinib (Fig. 6C); conversely, treatment with lapatinib + pertuzumab or lapatinib + cetuximab resulted in complete signal abrogation in cancer cells (Fig. 6C). At the morphologic level, the lingering tumor tissue retrieved after prolonged treatment with lapatinib and antibody consisted of residual pseudoglandular islands lined by pluristratified epithelium and embedded in large necrotic areas (Fig. 6C). Together, these results provide strong indication that the association of a dual EGFR/HER2 small molecule inhibitor and a monoclonal antibody directed against either EGFR or the EGFR/HER2 heterodimer might prove beneficial to treat cetuximab-resistant, quadruple-negative, HER2-amplified metastatic colorectal cancers in the clinical setting.

## DISCUSSION

Preclinical validation of potential therapeutic targets via the use of *in vivo* models is traditionally regarded as an obligatory step of anticancer drug development, but it is also considered a problematic issue. There is now increasing concern that what is still deemed a successful end point at the preclinical level—positive performance of a drug in xenografts of different human cancer cell lines—is in fact not predictive of a compound's efficacy in the clinical setting (44). The obvious objection is that immortalized cancer cells, which are commonly used in xenograft experiments, have been adapted to grow on plastic in the laboratory for decades and thus exhibit a genetic drift, a biologic compliance, and phenotypic features different from original cancers in patients.

Besides this evident flaw, another (often underestimated) drawback of such an approach is that the catalog of currently available cell lines is inevitably finite and possibly poor for some tumor types. The main reason for this inadequacy is an inherent difficulty in deriving long-term cell cultures from human tumors, which not only limits the spectrum of accessible cellular models but also introduces a heavy bias for the selection of aggressive subtypes, which are likely more amenable to *in vitro* propagation. This restricted compendium of representative “cases” is in conflict with the notion that each cancer in each individual is a separate entity, endowed with a unique natural history and riddled with a number of unpredictable patient-specific interacting events. Therefore, experiments with cell lines cannot recapitulate the wide heterogeneity of human malignancy that occurs among individuals on a population basis. The absence of genetic diversity, or at least a strong tendency towards an artificially uniform tumor evolution, is also a pitfall of genetically defined mouse models of cancer, which usually develop stereotypical lesions triggered by the same initiating oncogenic hit (45).

One robust way to proceed with efficient, high-fidelity drug development at the stage of *in vivo* validation while minimizing the effects of uncharacterized tumor heterogeneity would be to perform preclinical population-based studies. To do this, we reasoned that a practicable model was the use of a series of human cancer specimens directly transplanted into mice, to generate a study population that could be concomitantly profiled for biomarker assessment and randomized for prospective treatment with targeted agents (“xenopatient”). Liver metastases from colorectal carcinomas were chosen for this undertaking. By optimizing some



**Figure 6.** Effect of anti-EGFR and anti-HER2 therapies in cetuximab-resistant, *HER2*-amplified metastatic colorectal cancer xenopatiens. **A, B**, growth curves of tumors in xenopatiens derived from cetuximab-resistant, quadruple-negative, *HER2*-amplified cases M077 (A) and M091 (B) ( $n = 5$  for each treatment arm). **C**, immunohistochemistry assessment with the indicated antibodies of representative tumors from case M077 at the end of treatment. Scale bar, 100  $\mu\text{m}$ .



procedural tips, we were able to achieve high rates of successful sample engraftments in mice, thus ruling out a non-random prevalence of aggressive tumors. We then afforded the issue of model predictivity analytically by using a reiterative strategy; in particular, we exploited the molecular and clinical knowledge accumulated on targeted therapy with the anti-EGFR antibody cetuximab, in terms of response rates and biomarkers, and challenged the predictive value of the xenotransplantation setting by investigating whether what had been demonstrated in humans also applied to mice.

Several lines of evidence support the robustness and the predictive power of our strategy. (i) Notwithstanding their ectopic (subcutaneous) site of growth, metastatic colorectal cancer xenografts retained the morphologic characteristics of the corresponding patient's lesion, with aspects of glandular differentiation, mucinous histology, or anaplastic pleomorphism that were in agreement with the original phenotypes. (ii) A genome-wide survey of single-nucleotide polymorphism variations and a more oriented mutational analysis, both performed on a representative series of matched primary and xenografted cases, revealed that serial mouse passaging did not grossly alter the genetic makeup of tumors, at least when considering global copy number changes and hotspot oncogenic mutations. (iii) In the majority of cases, we monitored concordant effects of cetuximab in parallel xenograft cohorts derived from different specimens of the same tumor, suggesting that there was no critical sampling bias in the random selection of cancer fragments for implantation and that intrinsic genetic heterogeneity or regional clonal discrepancies did not influence the overall tumor sensitivity to therapy. (iv) The frequency of tumor regression, disease stabilization, and disease progression after cetuximab treatment was in line with the clinical data reported in humans. (v) Finally, identical to clinical observations, *KRAS* (codons 12 and 13) mutant xenografts were all resistant to EGFR blockade.

Consistency between patients and mice was also noticed for potential biomarkers that have weaker significance or await further validation. In accordance with clinical information, a gray zone of inconclusive findings emerged when we evaluated proposed positive response determinants, namely, *EGFR* gene copy number gain and overexpression of the EGFR ligands amphiregulin and ephregulin (30–36). A trend was observed whereby these parameters appeared to be enriched in responders, but the absence of unambiguous cutoff criteria confirmed that these biomarkers remain unfit for reliable case stratification. Instead, results were straightforward when we analyzed candidate predictors of lack of response, in particular *KRAS* rare mutations, *NRAS* and *BRAF* mutations (13–16): such genotypes all associated with resistance to cetuximab. By confirming in a prospective manner previous retrospective clinical data, our findings advocate inclusion of these negative biomarkers in the toolbox of surgical pathologists.

Our observation that *HER2* is amplified in a small percentage (2%–3%) of genetically unselected colorectal cancers is in agreement with previous reports (38–40). The unexpected and novel finding is the greater frequency of *HER2* amplification in cetuximab-resistant cases and its progressive enrichment along with refinement of genetic selection. Indeed, in *KRAS* wild-type colorectal cancer patients that displayed *de*

*novo* resistance to anti-EGFR therapies, high-grade *HER2* amplification was detected in 6 of 44 cases (13.6%). Further, in a more defined subset of *KRAS/NRAS/BRAF/PIK3CA* wild-type xenopatient in which treatment with cetuximab was ineffective, *HER2* amplification was detected in 4 of 11 cases, with an increase in prevalence up to 36%. Although absolute numbers remain small, it appears clear that the cases of *HER2* amplification all segregated with lack of response to anti-EGFR therapy, both in xenopatient and—importantly—in patients.

At the genetic level, the role of *HER2* as a potential driver of therapeutic resistance is supported by the mutual exclusivity between *HER2* amplification and mutations in components of substitute signaling pathways, including *KRAS*, *NRAS*, *BRAF*, and *PIK3CA*, which are also molecular determinants of resistance. Larger-scale retrospective trials are warranted to strengthen the role of *HER2* as a resistance biomarker, and prospective studies are necessary for ultimate validation in patients. Given the low frequency of *HER2* amplification in unselected populations, critical logistical aspects that trial designers will have to deal with are optimization of patient accrual and implementation of multiparametric genetic profiling to enrich for patients with quadruple-negative tumors.

The frequency of *HER2*-amplified cases in colorectal cancer is similar to that of other proposed biomarkers of resistance, including *BRAF* or *NRAS* (16). Although no approved therapies currently exist to effectively target *BRAF/NRAS*-mutant tumors, our results indicate that *HER2* amplification is not only a negative biomarker of resistance to cetuximab but also a positive biomarker of response to clinically used anti-*HER2* therapies. Indeed, we found that dual targeting of *HER2* and EGFR induced tumor regression when we used a combination of lapatinib and pertuzumab or, to a lesser extent, lapatinib and cetuximab. On the basis of the reliability of xenopatient in mimicking the human situation, we believe that our preclinical findings in *HER2*-amplified tumors can be considered as a reliable proxy of future findings in patients. In particular, the evident tumor shrinkage produced by the lapatinib + pertuzumab combination bodes well for prospective application of this therapeutic regimen in phase 2 clinical trials, of which we strongly encourage timely implementation.

In conclusion, we executed molecularly defined prospective trials in mice for treatment efficacy studies in metastatic colorectal cancer, with the major objective of advancing therapeutic strategies in a setting that best mimics the clinical context in patients. Our preclinical platform provides an instructive framework for additional biomarker discovery, for the generation of predictive classifiers for better patient stratification, and for testing novel investigational therapies that will undoubtedly improve the figures emerged from this initial effort.

## METHODS

### Specimen Collection and Annotation

A total of 150 consecutive tumor samples and matched normal samples were obtained from patients treated by liver metastasectomy at the Institute for Cancer Research and Treatment and Maurizioano Umberto I (Torino, Italy). All patients provided informed consent, and samples were procured and the study was conducted under the approval of the review boards of the institutions. Clinical and pathological data were entered and maintained in our prospective database.

## Molecular and Bioinformatic Analyses

Analyte extraction, gene copy number, and expression analysis and mutational profiling were performed as described (13, 19, 46). Part of the data on *EGFR* copy number has already been published (19). Primers for *HER2* gene copy number analysis were the following: forward, 5'-GTGAGTGATGGGGCTGAGTT-3'; reverse, 5'-CCAGGGAGGAGTGAGTTGTC-3'. Microsatellite instability was analyzed by the use of the MSI Analysis System (Promega). Cases featuring 2 or more mutant alleles were categorized as microsatellite unstable-high according to the revised Bethesda guidelines (47).

The samples gathered for the copy-number survey of 4 independent patients (38 tumors and 4 matched normal tissues) were handled and hybridized as previously described for Affymetrix Human 6.0 SNP array profiles (48). For detecting copy number variations, the Affymetrix Genotyping Console 3.0.2 and the Birdseed (v2) algorithm were used. The default external reference provided by the Affymetrix Genotyping Console platform was exploited as background. The results from the Affymetrix Genotyping Console analysis pipeline were assembled in a data matrix in which a numerical integer value ranging from 0 to 4 was assigned to each of the copy number probes (908226) present in the array. Scores of 0 and 1 were considered as calls for losses, and values of 3 and 4 were defined as calls for copy number gains. This matrix was used for subsequent analyses. Hierarchical clustering was performed on the copy number call matrix previously described with the use of Pearson correlation metrics and complete linkage to reveal similar clusters. All the computations were performed in the R Statistical Environment. To generate the frequency maps, each chromosome was parsed by the use of a sliding window covering 1600 copy-number probes and a sampling step of 800 probes. For each step, we evaluated the frequency of the most prevalent putative copy-number call according to the results obtained with the Affymetrix Genotyping Console software. The results were plotted as a heat-map using the *gedas* software (49).

## Explant Xenograft Models and In Vivo Treatments

Tumor implantation and expansion was performed as previously described (19). Established tumors (average volume 400 mm<sup>3</sup>) were treated with the following regimens, either single-agent or in combination: cetuximab (Merck) 20 mg/kg, twice-weekly; pertuzumab (Roche Genentech) 20 mg/kg, once-weekly; and lapatinib (Sequoia Research Products) 100 mg/kg, daily. Tumor size was evaluated once-weekly by caliper measurements and the approximate volume of the mass was calculated using the formula  $4/3\pi(d/2)^2 \cdot D/2$ , where *d* is the minor tumor axis and *D* is the major tumor axis. All animal procedures were approved by the Ethical Commission of the Institute for Cancer Research and Treatment and by the Italian Ministry of Health.

## In Situ Morphologic Analyses

Immunohistochemistry was performed as described (50). Images were captured with the Image-Pro Plus 6.2 software (Media Cybernetics) with the use of a BX60 Olympus microscope. HercepTest-based HER2 scoring followed the consensus panel recommendations for gastric cancer (51). FISH analysis was performed as described (52). For automated acquisition, the motorized Metafer Scanning System (Carl Zeiss MetaSystems GmbH) and AxioImager epifluorescence microscope (1 focus plane for DAPI and 13 focus planes for green and red spots) were used. Analysis of *HER2/CEP17* (chromosome 17 centromere) probes was performed automatically by Metafer through the PathVysion V2 software (approved by the Food and Drug Administration).

## Statistics

Statistical analyses were performed by the 2-tailed Student *t* test,  $\chi^2$  test, Fisher exact test, and binomial distribution calculations with the use of Excel or the R statistical environment. For all tests, the level of statistical significance was set at  $P < 0.05$ .

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Acknowledgments

We are particularly indebted to Rosa Giammarco (Merck, Italy) for the generous gift of cetuximab. We are grateful to Roche Genentech for providing pertuzumab. We thank Carla Boccaccio, Daniela Cantarella, Noemi Cavalera, Stefania Gastaldi, Simonetta Maria Leto, Barbara Lupo, Paolo Luraghi, Barbara Martinoglio, Paolo Michieli, Filippo Montemurro, Roberta Porporato, Eugenia Zanella, and Carlo Zanon for help with the experiments, discussion, and sharing reagents; Fabrizio Maina, Laura Tarditi, and Tuti Werdingsh for animal husbandry; Raffaella Albano, Stefania Giove, and Laura Palmas for technical assistance; and Antonella Cignetto and Daniela Gramaglia for secretarial assistance.

## Grant Support

The main financial support for this work was provided by AIRC, Associazione Italiana per la Ricerca sul Cancro—2010 Special Program Molecular Clinical Oncology 5 × 1000, project 9970. The Contribution from MIUR FIRB, Ministero dell'Università e della Ricerca, Fondo per gli Investimenti della Ricerca di Base—Futuro in Ricerca (to A. Bertotti) is also acknowledged. Partial funding was provided by AIRC Investigator Grants (to A. Bardelli, P.M. Comoglio, E. Medico, M. Risio, and L. Trusolino); the EU Seventh Framework Programme, grant agreements 259015 (to A. Bardelli), 201279, and 201640 (to P.M. Comoglio); Regione Piemonte (to A. Bardelli, F. Di Nicolantonio, P.M. Comoglio, E. Medico, and L. Trusolino); FPRC, Fondazione Piemontese per la Ricerca sul Cancro (to A. Bardelli, F. Di Nicolantonio, E. Medico, and L. Trusolino); and OCGO, Oncologia Ca' Granda ONLUS (S. Siena).

Received May 16, 2011; revised August 17, 2011; accepted August 30, 2011, published OnlineFirst September 2, 2011.

## REFERENCES

- Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. *Nat Rev Cancer* 2009;9:489–99.
- Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. *Annu Rev Med* 2009;60:207–19.
- Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. *J Natl Cancer Inst* 2009;101:1308–24.
- Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. *Clin Ther* 2010;32:437–53.
- Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. *Lancet* 2010;375:1030–47.
- Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. *J Clin Oncol* 2010;28:1254–61.
- Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. *Cancer Res* 2007;67:2643–8.
- Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. *J Clin Oncol* 2008;26:374–9.
- Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009;27:663–71.

10. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009;360:1408–17.
11. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor kras and BRAF mutation status. *J Clin Oncol* 2011;29:2011–9.
12. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol* 2010;28:4697–705.
13. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol* 2008;26:5705–12.
14. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. *Clin Cancer Res* 2009;15:3184–8.
15. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. *Cancer Res* 2009;69:1851–7.
16. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilias G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010;11:753–62.
17. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:1626–34.
18. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008;359:1757–65.
19. Galimi F, Torti D, Sassi F, Isella C, Corà D, Gastaldi S, et al. Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: response to Met inhibition in patient xenografts and pathological correlations. *Clin Cancer Res* 2011;17:3146–56.
20. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. *Cell* 2008;133:994–1005.
21. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. *Science* 2007;318:1108–13.
22. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. *Proc Natl Acad Sci U S A* 2008;105:16224–9.
23. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. *Proc Natl Acad Sci U S A* 2008;105:4283–8.
24. Haddad R, Ogilvie RT, Croitoru M, Muniz V, Gryfe R, Pollet A, et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. *Ann Surg Oncol* 2004;11:977–82.
25. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004;351:337–45.
26. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. *J Clin Oncol* 2004;22:1201–8.
27. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. *J Clin Oncol* 2006;24:4914–21.
28. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. *N Engl J Med* 2007;357:2040–8.
29. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol* 2007;25:1658–64.
30. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. *J Clin Oncol* 2007;25:3238–45.
31. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. *Lancet Oncol* 2005;6:279–86.
32. Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. *Ann. Oncol* 2008;19:717–23.
33. Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, et al. Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. *BMC Cancer* 2009;9:303.
34. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. *J Clin Oncol* 2009;27:5924–30.
35. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. *J Clin Oncol* 2007;25:3230–7.
36. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. *J Clin Oncol* 2009;27:5068–74.
37. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. *Nat Rev Cancer* 2005;5:341–54.
38. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. *Mod Pathol* 2004;17:895–904.
39. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. *J Clin Pathol* 2007;60:768–72.
40. Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. *Hum Pathol* 2010;41:1577–85.
41. Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. *J Clin Oncol* 2010;28:1181–9.
42. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. *Cancer Cell* 2004;5:317–28.
43. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al. Spector, anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. *Oncogene* 2002;21:6255–63.
44. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. *Nature* 2010;467, 543–9.
45. Jonkers J, Berns A. Conditional mouse models of sporadic cancer. *Nat Rev Cancer* 2002;2:251–65.
46. Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, et al. Only a subset of Met-activated pathways are required to sustain oncogene addiction. *Sci Signal* 2009;2:ra80.

47. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;96:261–8.
48. Närvä E, Autio R, Rahkonen N, Kong L, Harrison N, Kitsberg D, et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. *Nat Biotechnol* 2010;28:371–7.
49. Fu L, Medico E. FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data. *BMC Bioinformatics* 2007;8:3.
50. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. *Nat. Med.* 2008;14:1351–6.
51. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. *Histopathology* 2008;52:797–805.
52. Marchió C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. *J Pathol* 2009;219:16–24.